the most important parts, but its excision is predicted to inhibit the immune cycle. Though this study was observed for a short period postoperatively, no local or distant recurrences were noted, which suggests that LND performed at the same time as DCN may not cause recurrence in a short period of time. Thus, TLS may control cancers in the primary site and each metastatic site. However, this phenomenon still requires further studies. The meaning of DCN cannot be understood without long-term observation. And there are no large-scale studies examining the usefulness of DCN in the ICI era. A large, long-term, prospective observational studies are going.5

Conclusion
In our cases, immunohistochemistry, pretreatment renal lesion biopsy, and DCN lesion were performed. Although the post-operative observation period was short, patients survived without any treatment after DCN. Whether DCN contributed to long-term survival or not, TLS was expressed in the DCN specimen of these cases treated with Nivo/Ipi.

Acknowledgment
The authors thank Edanz Group (https://en-author-service.s.edanz.com/ac) for editing a draft of this manuscript.

Conflict of interest
The authors declare no conflict of interest.

Approval of the research protocol by an institutional reviewer board
The protocol for this research project has been approved by a suitably constituted Ethics Committee of the institution, and it conforms to the provisions of the Declaration of Helsinki.

Informed consent
Informed consent for publication was obtained from the patients.

Registry and the registration no. of the study/trial
This case report was approved by the Institutional Review Board of Chiba University Hospital (IRB No.2554).

REFERENCES
1 Albiger L, Tannir NM, Barotto M et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020; 5(6): e001079. https://doi.org/10.1136/esmoopen-2020-001079.
2 Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunootherapy. Nat. Rev. Cancer 2019; 19: 307–25.
3 Groeneveld CS, Fontugne J, Cabel L et al. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. Eur. J. Cancer 2021; 17: 181–9.
4 Dai S, Zeng H, Liu Z et al. Intratumoral CXCL13+CD8+ T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. J. Immunother. Cancer 2021; 9(2): e001823. https://doi.org/10.1136/jitc-2020-001823.
5 Kuusk T, Abu-Ghanem Y, Mumtaz F, Powles T, Bex A. Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy. Curr. Opin. Urol. 2021; 31: 262–9.

Supporting information
Additional Supporting Information may be found in the online version of this article at the publisher’s web-site:

Figure S1. Immunohistochemical stains of the primary site at pretreatment, deferred cytoreductive nephrectomy, and tertiary lymphoid structure in case 1.

Figure S2. Immunohistochemical stains of the primary site at pretreatment, deferred cytoreductive nephrectomy, and tertiary lymphoid structure in case 2.

Editorial Comment

Editorial Comment to Expression of tertiary lymphoid structure in deferred cytoreductive nephrectomy of metastatic renal cell carcinoma treated with nivolumab plus ipilimumab

The combination of the immune checkpoint inhibitors (ICIs), nivolumab (Opivto; Ono Pharma/Bristol Myers Squib), an antibody that targets programmed death-1, plus ipilimumab (Yervoy; Bristol Myers Squib), an antibody that targets cytotoxic T-lymphocyte-associated antigen-4, has been rapidly introduced as first-line therapy for the treatment of metastatic renal cell cancer (RCC) within the International Metastatic Renal Cell Cancer Database Consortium (IMDC) intermediate/poor category.1,2 The paradigm of medical treatment for patients with metastatic RCC has been dramatically changing. Therefore, biomarkers to predict the response and prognosis of ICI therapy are urgently needed. Amongst such biomarkers, tertiary lymphoid structures (TLSs) are ectopic lymphoid organs that develop in non-lymphoid tissues.3,4 Currently, the presence of TLSs is considered to be one of the most important predictive and prognostic factors in immune therapy.3,4

†This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
In this issue of *IJU Case Reports*, Sazuka et al. reported two patients with metastatic renal cell carcinoma, who demonstrated a complete response after combined nivolumab plus ipilimumab therapy followed by the deferred cytoreductive nephrectomy. At the initiation of the nivolumab plus ipilimumab therapy, both patients were in the IMDC poor-risk category with multiple metastases. Because almost all metastatic sites disappeared following the ICIs combination, both patients underwent the deferred cytoreductive nephrectomy. Pathological analysis disclosed that there were no or only a few viable cancer cells present in the kidney. Instead, there were several TLSs near the necrotic tumor and a large number of lymphocytes in both cases. Although they did not receive any treatment after the cytoreductive nephrectomy, they both survived with no evidence of disease.

Accumulating evidence indicates that TLSs play a major role in controlling cancer cell invasion and metastasis. TLSs are not formed prenatally and are not present under normal conditions. TLSs are found in chronically inflamed locations, which include persistent pathogen infection, autoimmune disorders, allograft rejection, and cancer. Despite developing evidence that TLSs are intrinsic to the immune response in cancer, their application as not only therapeutic tools but also biomarkers is far from real-world clinical practice. Therefore, further investigation is necessary to utilize the finding of TLSs effectively and to obtain the clinical benefit for cancer patients.

**Conflict of interest**

The author declares no conflict of interest.

**References**

1. Motzer RJ, Tannir NM, McDermott DF et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *N. Engl. J. Med.* 2018; 378: 1277–90.
2. Yuasa T, Masuda H, Yamamoto S, Numao N, Yonese J. Biomarkers to predict prognosis and response to checkpoint inhibitors. *Int. J. Clin. Oncol.* 2017; 22: 629–34.
3. Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. *Nat. Rev. Cancer.* 2019; 19: 307–25.
4. Munoz-Erazo L, Rhodes JL, Marion VC, Kemp RA. Tertiary lymphoid structures in cancer – considerations for patient prognosis. *Cell. Mol. Immunol.* 2020; 17: 570–5.
5. Sazuka T, Fujimoto A, Sato H et al. Expression of tertiary lymphoid structure in deferred cytoreductive nephrectomy of metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. *IJU Case Rep.* 2021; 4: 355–8.